肝脏p38α MAPK通过磷酸化FOXO1 S273在胰高血糖素信号中调控糖异生
该研究在小鼠原代肝细胞及多种基因修饰小鼠中探究p38 MAPK家族在胰高血糖素诱导肝糖输出中的作用。发现p38α MAPK通过磷酸化FOXO1 S273增强FOXO1稳定性促进糖异生,且胰高血糖素经EPAC2激活p38α,该通路为2型糖尿病潜在治疗靶点。
要点
- p38α MAPK而非其他p38亚型可磷酸化FOXO1 S273并增强FOXO1蛋白稳定性。
- 抑制p38α MAPK可阻断FOXO1 S273磷酸化、降低FOXO1水平并显著减弱胰高血糖素及禁食诱导的肝糖输出。
- FOXO1 S273A突变可降低饮食诱导肥胖小鼠的葡萄糖生成、改善糖耐量并增加胰岛素敏感性。
核心结论
- p38α MAPK通过刺激FOXO1 S273磷酸化介导胰高血糖素对健康和疾病状态下葡萄糖稳态的作用。
- 胰高血糖素诱导的EPAC2-p38α MAPK-pFOXO1-S273信号通路是治疗2型糖尿病的潜在治疗靶点。
研究设计与样本
- 研究将p38α、β、γ和δ MAPK siRNA转染原代肝细胞后检测胰高血糖素诱导的肝糖输出。
- 研究向肝脏特异性Foxo1敲除、肝脏特异性Irs1/Irs2双敲除和Foxo1S273D敲入小鼠注射携带p38α MAPK shRNA的8型腺相关病毒。
- 研究对Foxo1S273A敲入小鼠高脂饮食喂养10周。
- 研究在小鼠中进行了丙酮酸耐量试验、葡萄糖耐量试验、胰高血糖素耐量试验和胰岛素耐量试验,并分析肝脏基因表达谱及检测血清甘油三酯、胰岛素和胆固醇水平。
- 研究通过LC-MS体外分析p38α MAPK对叉头盒蛋白O1(FOXO1)的磷酸化。
主要发现
- p38α MAPK而非其他p38亚型刺激FOXO1-S273磷酸化并增加FOXO1蛋白稳定性,促进胰高血糖素刺激下的肝糖输出。
- 在肝细胞和小鼠模型中,抑制p38α MAPK可阻断FOXO1-S273磷酸化、降低FOXO1水平并显著减弱胰高血糖素及禁食诱导的肝糖输出。
- FOXO1缺陷或Foxo1 S273位点丝氨酸至天冬氨酸点突变(Foxo1S273D)可消除p38α MAPK抑制对肝糖输出的影响。
- Foxo1S273A突变降低饮食诱导肥胖小鼠的葡萄糖生成、改善糖耐量并增加胰岛素敏感性。
- 胰高血糖素通过cAMP激活的交换蛋白2(EPAC2)信号在肝细胞中激活p38α。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Hyperglucagonaemia-stimulated hepatic glucose production (HGP) contributes to hyperglycaemia during type 2 diabetes. A better understanding of glucagon action is important to enable efficient therapies to be developed for the treatment of diabetes. Here, we aimed to investigate the role of p38 MAPK family members in glucagon-induced HGP and determine the underlying mechanisms by which p38 MAPK regulates glucagon action. METHODS: p38α, β, γ and δ MAPK siRNAs were transfected into primary hepatocytes, followed by measurement of glucagon-induced HGP. Adeno-associated virus serotype 8 carrying p38α MAPK short hairpin RNA (shRNA) was injected into liver-specific Foxo1 knockout, liver-specific Irs1/Irs2 double knockout and Foxo1S273D knockin mice. Foxo1S273A knockin mice were fed a high-fat diet for 10 weeks. Pyruvate tolerance tests, glucose tolerance tests, glucagon tolerance tests and insulin tolerance tests were carried out in mice, liver gene expression profiles were analysed and serum triglyceride, insulin and cholesterol levels were measured. Phosphorylation of forkhead box protein O1 (FOXO1) by p38α MAPK in vitro was analysed by LC-MS. RESULTS: We found that p38α MAPK, but not the other p38 isoforms, stimulates FOXO1-S273 phosphorylation and increases FOXO1 protein stability, promoting HGP in response to glucagon stimulation. In hepatocytes and mouse models, inhibition of p38α MAPK blocked FOXO1-S273 phosphorylation, decreased FOXO1 levels and significantly impaired glucagon- and fasting-induced HGP. However, the effect of p38α MAPK inhibition on HGP was abolished by FOXO1 deficiency or a Foxo1 point mutation at position 273 from serine to aspartic acid (Foxo1S273D) in both hepatocytes and mice. Moreover, an alanine mutation at position 273 (Foxo1S273A) decreased glucose production, improved glucose tolerance and increased insulin sensitivity in diet-induced obese mice. Finally, we found that glucagon activates p38α through exchange protein activated by cAMP 2 (EPAC2) signalling in hepatocytes. CONCLUSIONS/INTERPRETATION: This study found that p38α MAPK stimulates FOXO1-S273 phosphorylation to mediate the action of glucagon on glucose homeostasis in both health and disease. The glucagon-induced EPAC2-p38α MAPK-pFOXO1-S273 signalling pathway is a potential therapeutic target for the treatment of type 2 diabetes.
引用
- Yang W, Liao W, Li X, et al. Hepatic p38α MAPK controls gluconeogenesis via FOXO1 phosphorylation at S273 during glucagon signalling in mice. Diabetologia. 2023. PMID: 37202506. doi:10.1007/s00125-023-05916-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。